Key points are not available for this paper at this time.
The safety and immunogenicity profiles of Ad26.COV2.S support further development of this vaccine candidate. (Funded by Johnson COV1001 ClinicalTrials.gov number, NCT04436276.).
Sadoff et al. (Wed,) studied this question.